Income StatementBalance SheetCash FlowSegments
ALM

Alamar Biosciences, Inc. Common Stock Cash Flow Statement

Operating, investing, and financing cash movements

Based on the Q1 2026 filing.

Net Cash From Operating-$20.3MNet Cash From Investing-$778.0KNet Cash From Financing$55.8MCapital Expenditures$600.0KDepreciation And Amortization$1.2MNet Change In Cash$34.6M
Latest FilingQ1 2026
Report Date2026-05-08

Financing

MetricQ1 '25Q1 '26
Proceeds from convertible debt—$56.5M
Net cash from financing activities$243.0K$55.8M
Proceeds from issuance of common stock$243.0K$1.8M
Payments Of Debt Issuance Costs—$324.0K
Payments Of Stock Issuance Costs—$2.2M

Investing

MetricQ1 '25Q1 '26
Capital expenditures$554.0K$600.0K
Net cash from investing activities$17.0M-$778.0K
Payments to Develop Software$428.0K$178.0K
Proceeds from maturities of short-term investments$18.0M—

Operating

MetricQ1 '25Q1 '26
Change in accounts payable$578.0K$1.3M
Change in accounts receivable$533.0K$6.9M
Change in inventories$2.4M$1.3M
Change in other assets-$182.0K$327.0K
Depreciation and amortization$888.0K$1.2M
Net cash from operating activities-$13.1M-$20.3M
Net income-$7.7M-$21.3M
Fair Value Adjustment of Warrants-$19.0K$84.0K
Stock-based compensation$619.0K$1.5M
Accretion (Amortization) of Discounts and Premiums, Investments$208.0K—
Amortization expense related to capitalized debt issuance costs$42.0K$67.0K
Convertible Note Issuance Costs Included In Net Income—$361.0K
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax$134.0K-$165.0K
Increase (Decrease) in Contract with Customer, Asset-$282.0K—
Increase Decrease In Net Investment In Sales Type Lease-$86.0K—
Operating lease liabilities-$463.0K-$1.1M
Other current liabilities-$5.0M-$1.2M
Increase (Decrease) in Prepaid Expense and Other Assets-$191.0K$2.0M
Loss On Remeasurement Of Convertible Notes—$8.6M
Operating lease right-of-use asset amortization$465.0K$461.0K

Free Cash Flow

MetricQ1 '25Q1 '26
Free cash flow-$13.6M-$20.9M

Other

MetricQ1 '25Q1 '26
Effect of exchange rate changes on cash$133.0K-$52.0K
Net increase (decrease) in cash$4.3M$34.6M
Deferred Financing And Deferred Offering Costs Included In Accrued Liabilities—$2.1M
Equipment Transferred To Inventory$169.0K$214.0K
Property And Equipment Included In Accounts Payable And Accrued Liabilities$457.0K$583.0K
Vesting Of Early Exercised Stock Options$7.0K$102.0K

Supplemental

MetricQ1 '25Q1 '26
Interest paid$3.0K$156.0K